• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

实用且高效的获益与风险评估方法学:SOCRATES 试验的应用。

Methodologies for pragmatic and efficient assessment of benefits and harms: Application to the SOCRATES trial.

机构信息

Biostatistics Center, George Washington University, Washington, DC, USA.

AstraZeneca, Research and Development, Gothenburg, Sweden.

出版信息

Clin Trials. 2020 Dec;17(6):617-626. doi: 10.1177/1740774520941441. Epub 2020 Jul 15.

DOI:10.1177/1740774520941441
PMID:32666831
Abstract

BACKGROUND/AIMS: Standard approaches to trial design and analyses can be inefficient and non-pragmatic. Failure to consider a range of outcomes impedes evidence-based interpretation and reduces power. Traditional approaches synthesizing information obtained from separate analysis of each outcome fail to incorporate associations between outcomes and recognize the cumulative nature of outcomes in individual patients, suffer from competing risk complexities during interpretation, and since efficacy and safety analyses are often conducted on different populations, generalizability is unclear. Pragmatic and efficient approaches to trial design and analyses are needed.

METHODS

Approaches providing a pragmatic assessment of benefits and harms of interventions, summarizing outcomes experienced by patients, and providing sample size efficiencies are described. Ordinal outcomes recognize finer gradations of patient responses. Desirability of outcome ranking is an ordinal outcome combining benefits and harms within patients. Analysis of desirability of outcome ranking can be based on rank-based methodologies including the desirability of outcome ranking probability, the win ratio, and the proportion in favor of treatment. Partial credit analyses, involving grading the levels of the desirability of outcome ranking outcome similar to an academic test, provides an alternative approach. The methodologies are demonstrated using the acute stroke or transient ischemic attack treated with aspirin or ticagrelor and patient outcomes study (SOCRATES; NCT01994720), a randomized clinical trial.

RESULTS

Two 5-level ordinal outcomes were developed for SOCRATES. The first was based on a modified Rankin scale. The odds ratio is 0.86 (95% confidence interval = 0.75, 0.99; = 0.04) indicating that the odds of worse stroke categorization for a trial participant assigned to ticagrelor is 0.86 times that of a trial participant assigned to aspirin. The 5-level desirability of outcome ranking outcome incorporated and prioritized survival; the number of strokes, myocardial infarction, and major bleeding events; and whether a stroke event was disabling. The desirability of outcome ranking probability and win ratio are 0.504 (95% confidence interval = 0.499, 0.508; = 0.10) and 1.11 (95% confidence interval = 0.98, 1.26; = 0.10), respectively, implying that the probability of a more desirable result with ticagrelor is 50.4% and that a more desirable result occurs 1.11 times more frequently on ticagrelor versus aspirin.

CONCLUSION

Ordinal outcomes can improve efficiency through required pre-specification, careful construction, and analyses. Greater pragmatism can be obtained by composing outcomes within patients. Desirability of outcome ranking provides a global assessment of the benefits and harms that more closely reflect the experience of patients. The desirability of outcome ranking probability, the proportion in favor of treatment, the win ratio, and partial credit can more optimally inform patient treatment, enhance the understanding of the totality of intervention effects on patients, and potentially provide efficiencies over standard analyses. The methods provide the infrastructure for incorporating patient values and estimating personalized effects.

摘要

背景/目的:标准的试验设计和分析方法可能效率低下且不切实际。未能考虑一系列结果会阻碍基于证据的解释并降低效能。传统的方法综合了对每个结果分别进行分析所获得的信息,但无法结合结果之间的关联,也无法认识到个体患者结果的累积性质,在解释过程中会受到竞争风险的复杂性的影响,而且由于疗效和安全性分析通常在不同人群中进行,因此其普遍性尚不清楚。需要采用实用且高效的试验设计和分析方法。

方法

本文介绍了一些实用的评估干预措施的获益和危害、总结患者所经历的结果并提供样本量效率的方法。有序结果可识别患者反应的更细微差异。对结果排序的期望是一种在患者内部结合获益和危害的有序结果。结果排序期望的分析可以基于基于排名的方法,包括结果排序期望概率、赢率和治疗优势比。涉及对结果排序期望结果进行分级的部分信用分析(类似于学术测试)提供了一种替代方法。本文使用急性中风或短暂性脑缺血发作患者接受阿司匹林或替格瑞洛治疗和患者结局研究(SOCRATES;NCT01994720)的数据,对这些方法进行了演示,该研究为一项随机临床试验。

结果

为 SOCRATES 开发了两个 5 级有序结果。第一个基于改良的Rankin 量表。比值比为 0.86(95%置信区间=0.75,0.99;=0.04),表明接受替格瑞洛治疗的试验参与者发生更严重中风分类的可能性是接受阿司匹林治疗的试验参与者的 0.86 倍。5 级结果排序期望结果纳入并优先考虑了生存;中风、心肌梗死和大出血事件的数量;以及中风事件是否致残。结果排序期望概率和赢率分别为 0.504(95%置信区间=0.499,0.508;=0.10)和 1.11(95%置信区间=0.98,1.26;=0.10),这意味着使用替格瑞洛的更理想结果的概率为 50.4%,且替格瑞洛与阿司匹林相比更理想的结果发生的频率高 1.11 倍。

结论

有序结果可通过预先指定、精心构建和分析来提高效率。通过在患者内部组合结果可以获得更大的实用性。结果排序期望提供了对获益和危害的全面评估,更能反映患者的体验。结果排序期望概率、治疗优势比、赢率和部分信用可以更优化地为患者治疗提供信息,增强对干预措施对患者整体效果的理解,并可能提供优于标准分析的效率。这些方法为纳入患者价值观和估计个体化效应提供了基础。

相似文献

1
Methodologies for pragmatic and efficient assessment of benefits and harms: Application to the SOCRATES trial.实用且高效的获益与风险评估方法学:SOCRATES 试验的应用。
Clin Trials. 2020 Dec;17(6):617-626. doi: 10.1177/1740774520941441. Epub 2020 Jul 15.
2
Efficacy and Safety of Ticagrelor in Relation to Aspirin Use Within the Week Before Randomization in the SOCRATES Trial.SOCRATES 试验中随机分组前一周内使用阿司匹林与替格瑞洛疗效和安全性的关系。
Stroke. 2018 Jul;49(7):1678-1685. doi: 10.1161/STROKEAHA.118.020553. Epub 2018 Jun 18.
3
Estimated treatment effect of ticagrelor versus aspirin by investigator-assessed events compared with judgement by an independent event adjudication committee in the SOCRATES trial.SOCRATES 试验中研究者评估事件与独立事件评估委员会判断相比替格瑞洛与阿司匹林的估计治疗效果。
Int J Stroke. 2019 Dec;14(9):908-914. doi: 10.1177/1747493019851282. Epub 2019 May 15.
4
Risk for Major Bleeding in Patients Receiving Ticagrelor Compared With Aspirin After Transient Ischemic Attack or Acute Ischemic Stroke in the SOCRATES Study (Acute Stroke or Transient Ischemic Attack Treated With Aspirin or Ticagrelor and Patient Outcomes).SOCRATES 研究(阿司匹林或替格瑞洛治疗的急性卒中和短暂性脑缺血发作以及患者结局)中,短暂性脑缺血发作或急性缺血性卒中患者接受替格瑞洛与阿司匹林治疗后的大出血风险
Circulation. 2017 Sep 5;136(10):907-916. doi: 10.1161/CIRCULATIONAHA.117.028566. Epub 2017 Jun 27.
5
Comparative Methodological Assessment of the Randomized GLOBAL LEADERS Trial Using Total Ischemic and Bleeding Events.使用总缺血和出血事件对随机化全球领导者试验进行比较方法学评估。
Circ Cardiovasc Qual Outcomes. 2020 Aug;13(8):e006660. doi: 10.1161/CIRCOUTCOMES.120.006660. Epub 2020 Jul 30.
6
Efficacy and safety of ticagrelor versus aspirin in acute stroke or transient ischaemic attack of atherosclerotic origin: a subgroup analysis of SOCRATES, a randomised, double-blind, controlled trial.替格瑞洛与阿司匹林在动脉粥样硬化性起源的急性卒中和短暂性脑缺血发作中的疗效和安全性:SOCRATES 随机、双盲、对照试验的亚组分析。
Lancet Neurol. 2017 Apr;16(4):301-310. doi: 10.1016/S1474-4422(17)30038-8. Epub 2017 Feb 23.
7
Ticagrelor in Acute Stroke or Transient Ischemic Attack in Asian Patients: From the SOCRATES Trial (Acute Stroke or Transient Ischemic Attack Treated With Aspirin or Ticagrelor and Patient Outcomes).替格瑞洛用于亚洲患者急性卒中或短暂性脑缺血发作:来自SOCRATES试验(阿司匹林或替格瑞洛治疗急性卒中或短暂性脑缺血发作及患者预后)
Stroke. 2017 Jan;48(1):167-173. doi: 10.1161/STROKEAHA.116.014891. Epub 2016 Nov 29.
8
Time to Loading Dose and Risk of Recurrent Events in the SOCRATES Trial.SOCRATES 试验中负荷剂量时间与再发事件风险。
Stroke. 2019 Mar;50(3):675-682. doi: 10.1161/STROKEAHA.118.022675.
9
Ticagrelor and Aspirin or Aspirin Alone in Acute Ischemic Stroke or TIA.替卡格雷与阿司匹林或阿司匹林单用在急性缺血性卒中和 TIA。
N Engl J Med. 2020 Jul 16;383(3):207-217. doi: 10.1056/NEJMoa1916870.
10
Ticagrelor versus Aspirin in Acute Stroke or Transient Ischemic Attack.替卡格雷与阿司匹林用于急性卒中和短暂性脑缺血发作。
N Engl J Med. 2016 Jul 7;375(1):35-43. doi: 10.1056/NEJMoa1603060. Epub 2016 May 10.

引用本文的文献

1
Development of a conceptual framework for defining trial efficiency.定义试验效率的概念框架的发展。
PLoS One. 2024 May 23;19(5):e0304187. doi: 10.1371/journal.pone.0304187. eCollection 2024.
2
Application of desirability of outcome ranking to the milking in non-vigorous infants trial.应用结局意愿排序在非活力婴儿哺乳试验中的应用。
Early Hum Dev. 2024 Feb;189:105928. doi: 10.1016/j.earlhumdev.2023.105928. Epub 2024 Jan 5.
3
Optimising the analysis of vascular prevention trials: Re-Assessment of the TARDIS trial, the first prevention trial to adopt an ordinal primary outcome measure.
优化血管预防试验分析:对TARDIS试验的重新评估,这是首个采用有序主要结局指标的预防试验。
Contemp Clin Trials Commun. 2023 Jul 5;35:101186. doi: 10.1016/j.conctc.2023.101186. eCollection 2023 Oct.
4
Study protocol for a randomized clinical trial to assess 7 versus 14-days of treatment for Pseudomonas aeruginosa bloodstream infections (SHORTEN-2 trial).一项评估铜绿假单胞菌血流感染 7 天与 14 天治疗方案的随机临床试验研究方案(SHORTEN-2 试验)。
PLoS One. 2022 Dec 22;17(12):e0277333. doi: 10.1371/journal.pone.0277333. eCollection 2022.
5
A desirability of outcome ranking (DOOR) for periprosthetic joint infection - a Delphi analysis.人工关节感染的预后排名期望度(DOOR)——德尔菲分析
J Bone Jt Infect. 2022 Nov 10;7(6):221-229. doi: 10.5194/jbji-7-221-2022. eCollection 2022.
6
Design and Analysis of Studies Based on Hierarchical Composite Endpoints: Insights from the DARE-19 Trial.基于层次复合终点的研究设计与分析:来自 DARE-19 试验的启示。
Ther Innov Regul Sci. 2022 Sep;56(5):785-794. doi: 10.1007/s43441-022-00420-1. Epub 2022 Jun 14.
7
Using a Composite Maternal-Infant Outcome Measure in Tuberculosis-Prevention Studies Among Pregnant Women.使用孕产妇-婴儿复合结局指标评估结核病预防研究中的孕妇。
Clin Infect Dis. 2021 Aug 2;73(3):e587-e593. doi: 10.1093/cid/ciaa1674.